Compare IAC/Interactivecorp (PPLI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Vertex Pharmaceuticals Incorporated — how do they compare? IAC/Interactivecorp trades at $43.41 (market cap $3.28B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 37.3× IAC/Interactivecorp's market cap. Which is the better fit depends on your goals.
| PPLI | VRTX | |
|---|---|---|
Market Cap | $3.28B | $122.33B |
Sector | Media | Health |
52-Week High | $47.62 | $529.59 |
52-Week Low | $31.52 | $366.54 |
Enterprise Value | $3.58B | $117.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $44.09, down 0.99% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows mixed fundamentals with declining revenue from $5.2B in 2022 to $2.4B in 2025 and negative EPS misses in recent quarters, though net income margin improved to -4.35% from -14.19% in 2024. Recent news highlights potential MGM acquisition talks and upcoming Q2 2026 earnings call on August 4th.
The stock presents a value opportunity with P/B of 0.73 and strong analyst support (63.6% buy rating, $55.40 consensus target), but faces execution risks from consecutive earnings misses and negative cash flow trends. Key catalysts include MGM deal progress and Q2 results, while competitive pressures and volatile profitability remain concerns.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
